[Federal Register Volume 89, Number 182 (Thursday, September 19, 2024)]
[Notices]
[Page 76863]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21363]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Cancer 
Institute Clinical Trials and Translational Research Advisory 
Committee.
    This will be a hybrid meeting held in-person and virtually and will 
be open to the public. Individuals who plan to attend in-person or view 
the virtual meeting and need special assistance or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting. The meeting can be accessed from the NIH 
Videocast at the following link: https://videocast.nih.gov/.

    Name of Committee: National Cancer Institute Clinical Trials and 
Translational Research Advisory Committee.
    Date: November 6, 2024.
    Time: 8:30 a.m. to 3:00 p.m.
    Agenda: Strategic Discussion of NCI's Clinical and Translational 
Research Programs.
    Place: National Cancer Institute, 9609 Medical Center Drive, 
East Wing, Conference Room TE406/408/410, Rockville, MD 20850 (In 
Person and Virtual Meeting).
    Contact Person: Sheila A. Prindiville, M.D., M.P.H., Director, 
Coordinating Center for Clinical Trials, National Cancer Institute, 
National Institutes of Health, 9609 Medical Center Drive, Room 
6W136, Rockville, MD 20850, 240-276-6173, <a href="/cdn-cgi/l/email-protection#aadad8c3c4cec3dcd9eac7cbc3c684c4c3c284cdc5dc"><span class="__cf_email__" data-cfemail="1464667d7a707d62675479757d783a7a7d7c3a737b62">[email protected]</span></a>.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NCI-Shady Grove campus. All 
visitors will be asked to show one form of identification (for 
example, a government-issued photo ID, driver's license, or 
passport) and to state the purpose of their visit.
    Information is also available on the Institute's/Center's home 
page: http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: September 13, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee 
Policy.
[FR Doc. 2024-21363 Filed 9-18-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>